Mark Avagliano
CIK 1783503 · Chief Business Officer · last filed 2024-09-18
Mark Avagliano is a Chief Business Officer who has filed 12 SEC Form 4 insider transactions across 1 company since 2019. The most recent filing, for GTHX, was dated Sep 18, 2024. Across all open-market trades the lifetime net is −$73.6K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
12
-$73.6K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| G1 Therapeutics, Inc. (GTHX) Delisted | Chief Business Officer | 26,035 | $7.15 | $186.2K | -$73.6K | 12 | 2024-09-18 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-18 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | −242,045 | $0 | EDGAR |
| 2024-07-08 | G1 Therapeutics, Inc. (GTHX) Delisted | Sell (S) | −2,638 | -$6.6K | EDGAR |
| 2024-07-03 | G1 Therapeutics, Inc. (GTHX) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2024-05-15 | G1 Therapeutics, Inc. (GTHX) Delisted | Sell (S) | −8,151 | -$39.0K | EDGAR |
| 2024-03-22 | G1 Therapeutics, Inc. (GTHX) Delisted | Grant (A) | +100,000 | $0 | EDGAR |
| 2024-01-08 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | +40,679 | -$12.6K | EDGAR |
| 2023-05-12 | G1 Therapeutics, Inc. (GTHX) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2023-01-05 | G1 Therapeutics, Inc. (GTHX) Delisted | Grant (A) | +20,600 | $0 | EDGAR |
| 2022-01-05 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | +10,555 | -$15.3K | EDGAR |
| 2021-01-05 | G1 Therapeutics, Inc. (GTHX) Delisted | Grant (A) | +11,000 | $0 | EDGAR |